<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Anti-CD20 monoclonal antibodies are currently used for non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> treatment and Rituximab (MabThera) and ibritumomab-tiuxetan (Zevalin) currently approved for clinical use </plain></SENT>
<SENT sid="1" pm="."><plain>Rituximab has improved survival of patients with follicular and diffuse large B cells <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Rituximab is safe with uncommon side effects mainly observed during the first infusion </plain></SENT>
<SENT sid="3" pm="."><plain>It is basically used associated with chemotherapy every three weeks and also as maintenance therapy for relapsed follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>A better understand of its mechanisms of action has allowed to develop new generation of monoclonal antibody currently tested in clinical trials </plain></SENT>
</text></document>